In­tel­li­a's CRISPR pro­gram that ed­its genes di­rect­ly in pa­tients shows dura­bil­i­ty in AT­TR amy­loi­do­sis

The first in vi­vo CRISPR/Cas9 gene edit­ing pro­gram has some new dura­bil­i­ty da­ta show­ing sus­tained re­duc­tion of a tox­ic pro­tein in AT­TR amy­loi­do­sis at all …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER